p-mTor expression is associated with better prognosis in luminal breast carcinoma

Francisco Beca, Rosario Andre, Duarte Saraiva Martins, Tiago Bilhim, Diana Martins, Fernando Schmitt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. Methods In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. Results 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lowergrade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. Conclusions p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs.

Original languageEnglish
Pages (from-to)961-967
Number of pages7
JournalJournal of Clinical Pathology
Volume67
Issue number11
DOIs
Publication statusPublished - 1 Nov 2014

Fingerprint

Sirolimus
Breast Neoplasms
Disease-Free Survival
Survival
Lymph Nodes
Outcome Assessment (Health Care)
Neoplasms
Phosphatidylinositol 3-Kinases
Retrospective Studies

Cite this

Beca, Francisco ; Andre, Rosario ; Martins, Duarte Saraiva ; Bilhim, Tiago ; Martins, Diana ; Schmitt, Fernando. / p-mTor expression is associated with better prognosis in luminal breast carcinoma. In: Journal of Clinical Pathology. 2014 ; Vol. 67, No. 11. pp. 961-967.
@article{62b1d4ea1d114acc9e36d0ca73ee5341,
title = "p-mTor expression is associated with better prognosis in luminal breast carcinoma",
abstract = "Aims Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. Methods In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. Results 43.8{\%} of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lowergrade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. Conclusions p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs.",
author = "Francisco Beca and Rosario Andre and Martins, {Duarte Saraiva} and Tiago Bilhim and Diana Martins and Fernando Schmitt",
year = "2014",
month = "11",
day = "1",
doi = "10.1136/jclinpath-2014-202320",
language = "English",
volume = "67",
pages = "961--967",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "British Medical Assoc",
number = "11",

}

p-mTor expression is associated with better prognosis in luminal breast carcinoma. / Beca, Francisco; Andre, Rosario; Martins, Duarte Saraiva; Bilhim, Tiago; Martins, Diana; Schmitt, Fernando.

In: Journal of Clinical Pathology, Vol. 67, No. 11, 01.11.2014, p. 961-967.

Research output: Contribution to journalArticle

TY - JOUR

T1 - p-mTor expression is associated with better prognosis in luminal breast carcinoma

AU - Beca, Francisco

AU - Andre, Rosario

AU - Martins, Duarte Saraiva

AU - Bilhim, Tiago

AU - Martins, Diana

AU - Schmitt, Fernando

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Aims Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. Methods In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. Results 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lowergrade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. Conclusions p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs.

AB - Aims Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. Methods In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. Results 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lowergrade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. Conclusions p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs.

UR - http://www.scopus.com/inward/record.url?scp=84908476208&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2014-202320

DO - 10.1136/jclinpath-2014-202320

M3 - Article

VL - 67

SP - 961

EP - 967

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 11

ER -